Methods for determining risk of developing alzheimer's disease by detecting mutations in the presenilin 2 (PS-2) gene
US6485911B1 · kind B1 · utility
7Cited by
5References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 11, 2000 |
| Grant date | Nov 26, 2002 |
| Priority date | — |
| Expiry date | Aug 11, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes the identification, isolation and cloning of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease. Also identified are presenilin homologue genes in mice, C. elegans and D. melanogaster. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the constructions of transgenic animals expressing the mutant genes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.